



Demographics and socioeconomic

Total Population (in 1000) (2020)	11,402.53
Population <1 year of age (in 1000) (2020)	254.46
Population 1 year of age (in 1000) (2020)	253.51
Population <5 years of age (in 1000) (2020)	1,262.94
Women of childbearing age (in 1000) (2020)	9,729.91
Infant Mortality Rate (per 1000 live births) (2016-17)*	59.0
Gross national income (US\$ per capita) current value (2020)	1,250.0
National Health Expenditure Public (2018)	0.9
National Health Expenditure Private (2018)	3.8

* survey

Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 2016-2020.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 3 times in 2020.
- 79% of spending on routine immunization is financed using government funds.
- No information is available on spending on vaccine purchase financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	
Hepatitis B	
HPV	
Influenza	
MMR1	
MMR2	2016
Pentavalent	
Pneumococcal Conjugate	2018
Rotavirus	2014
Tdap	
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	

Immunization Schedule

	Doses					
	1	2	3	4	5	6
HTI						
BCG	B					
HepB pediatric						
DTP-Hib						
DTP-Hib-HepB	S6	S10	S14			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV						
DTP					M15	
Influenza pediatric						
IPV	S6					
OPV	S0	S10	S14	M9		
MR	M9	M12-23				
Pneumoco conjugate	S6	S10	S14			
Rotavirus	S6	S10				
Td	1st contact	+M1	+M6	+Y1	+Y1	
Tdap						
HPV						

Vaccination Coverage




Surveillance indicators

Acute flaccid paralysis (AFP)	2020
Number of AFP suspected cases	8
AFP rate per 100,000 population <15 years old	0.22
% of cases with 1 adequate samples	38
% of cases investigated within <48 hours	50
% sites reporting	92


Measles-rubella (MR)	2020
Number of MR suspected cases	142
% of cases with adequate investigation	92
% of cases with adequate blood samples	95
% of samples received in laboratory <=5 days	58
% of laboratory samples results <=4 days	58




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend

- NB/nb-newborn
- M/m -month
- Y/y-year
- WCBA-women of childbearing age
- with stockout
- no stockout
- no data available

Vaccine Stockout

HTI	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes	●	●	●	●	●			●
BCG	●	●	●	●	●	●		●
Disposable syringes	●		●		●			
DTP		●	●	●	●	●		●
HepB		●	●	●	●			
Hib		●	●	●	●			
Influenza								
IPV			●	●	●	●		●
Measles	●	●	●	●	●			●
Pneumo. conjugate						●		●
Polio	●		●	●	●	●		●
Reconst. syringes	●		●	●	●			●
Rotavirus			●	●	●	●		●
Safety boxes	●			●	●			●
Tdap				●				●
TT	●		●			●		●
Yellow fever								